Gary Blackford named to board of directors at EnteroMedics
"On behalf of the board of directors, I would like to thank Mr. Jansz for his contribution and service to the company. We wish him well in his future endeavors," EnteroMedics Chairman of the Board Mark Knudson said. "We are extremely fortunate to have Mr. Blackford join our board at such an important time for the company. His insight and guidance will be invaluable as we continue to work towards our goals of expanding vBloc usage and obtaining broad reimbursement coverage."
Blackford comes to EnteroMedics with more than 30 years of experience as an executive in the health care industry. His most recent appointment was as the CEO of Universal Hospital Services from 2002 to 2015. Prior to that, he served as the CEO of Curative Health Services from 2001-02. Blackford served in executive roles from 1994 to 1998 at various pharmacy benefit management companies.
EnteroMedics focuses on developing medical devices using neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.
"vBloc Therapy has demonstrated a great potential to play a crucial role within the obesity treatment paradigm," Blackford said. "I am delighted to join the EnteroMedics Board, and look forward to helping the company achieve its long-term goals."